The role of amino acid metabolism in inflammatory bowel disease and other inflammatory diseases

Front Immunol. 2023 Oct 23:14:1284133. doi: 10.3389/fimmu.2023.1284133. eCollection 2023.

Abstract

Inflammation is a characteristic symptom of the occurrence and development of many diseases, which is mainly characterized by the infiltration of inflammatory cells such as macrophages and granulocytes, and the increased release of proinflammatory factors. Subsequently, macrophage differentiates and T cells and other regulated factors exhibit anti-inflammatory function, releasing pro- and anti-inflammatory factors to maintain homeostasis. Although reports define various degrees of metabolic disorders in both the inflamed and non-inflamed parts of inflammatory diseases, little is known about the changes in amino acid metabolism in such conditions. This review aims to summarize amino acid changes and mechanisms involved in the progression of inflammatory bowel disease (IBD) and other inflammatory diseases. Since mesenchymal stem cells (MSCs) and their derived exosomes (MSC-EXO) have been found to show promising effects in the treatment of IBD and other inflammatory diseases,their potential in the modulation of amino acid metabolism in the treatment of inflammation is also discussed.

Keywords: amino acid metabolism; exosome; inflammation; inflammatory bowel disease; mesenchymal stem cell.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids / metabolism
  • Anti-Inflammatory Agents / metabolism
  • Humans
  • Inflammation / metabolism
  • Inflammatory Bowel Diseases* / metabolism
  • Macrophages / metabolism

Substances

  • Anti-Inflammatory Agents
  • Amino Acids

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This project is supported by the Grant of the Scientific Project of Jiangsu Health Commission (Grant no.Z2020038); the Grant of the Open Project of Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy (Grant no.XZSYSKF2020032); Jiangsu 333 High-Level Talents Training Project and Changzhou High-Level Medical Talents Training Project (Grant no.2022CZBJ111).